JP2017522886A - ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用 - Google Patents

ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用 Download PDF

Info

Publication number
JP2017522886A
JP2017522886A JP2017504353A JP2017504353A JP2017522886A JP 2017522886 A JP2017522886 A JP 2017522886A JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017504353 A JP2017504353 A JP 2017504353A JP 2017522886 A JP2017522886 A JP 2017522886A
Authority
JP
Japan
Prior art keywords
antibody
htt
seq
amino acid
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017504353A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522886A5 (https=
Inventor
メイヤー，マーセル
グリム，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurimmune Holding AG
Original Assignee
Neurimmune Holding AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurimmune Holding AG filed Critical Neurimmune Holding AG
Publication of JP2017522886A publication Critical patent/JP2017522886A/ja
Publication of JP2017522886A5 publication Critical patent/JP2017522886A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
JP2017504353A 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用 Pending JP2017522886A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14179004.8 2014-07-29
EP14179004 2014-07-29
PCT/EP2015/067327 WO2016016278A2 (en) 2014-07-29 2015-07-29 Human-derived anti-huntingtin (htt) antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020096056A Division JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用

Publications (2)

Publication Number Publication Date
JP2017522886A true JP2017522886A (ja) 2017-08-17
JP2017522886A5 JP2017522886A5 (https=) 2018-10-18

Family

ID=51225442

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017504353A Pending JP2017522886A (ja) 2014-07-29 2015-07-29 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020096056A Active JP7235939B2 (ja) 2014-07-29 2020-06-02 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP2023006564A Active JP7562168B2 (ja) 2014-07-29 2023-01-19 ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用

Country Status (11)

Country Link
US (3) US10556946B2 (https=)
EP (2) EP4406549A3 (https=)
JP (3) JP2017522886A (https=)
KR (1) KR102643395B1 (https=)
CN (2) CN113651887A (https=)
AU (3) AU2015295441B2 (https=)
CA (1) CA2954738A1 (https=)
EA (1) EA201790165A1 (https=)
IL (2) IL250180A0 (https=)
MX (3) MX391037B (https=)
WO (1) WO2016016278A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
EP4406549A3 (en) * 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
US11851487B2 (en) * 2019-04-01 2023-12-26 Rensselaer Polytechnic Institute Methods and systems for detecting peptide aggregates
TW202110878A (zh) 2019-05-16 2021-03-16 法商賽諾菲公司 在神經系統中表現抗原結合蛋白
EP4041308A1 (en) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4093426A1 (en) 2020-01-24 2022-11-30 University of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
CN111909265B (zh) * 2020-08-25 2022-02-11 中国人民解放军军事科学院军事医学研究院 一种结合破伤风毒素重链c端结构域的人源抗体及应用
MX2023008744A (es) 2021-01-29 2023-10-02 Illimis Therapeutics Inc Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis.
WO2023099788A1 (en) 2021-12-03 2023-06-08 Neurimmune Ag Novel potency assay for antibody-based drugs and useful means therefor
CN114334076B (zh) * 2021-12-23 2025-03-21 华中科技大学 一种药食同源中药玉竹的重金属概率风险评估方法及系统
CN120476138A (zh) * 2022-12-07 2025-08-12 阿乐凯抗体治疗有限公司 抗亨廷顿蛋白抗体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232052A1 (en) * 2002-01-28 2003-12-18 Ali Khoshnan Antibodies that bind to an epitope on the Huntington's disease protein
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
JP2010514454A (ja) * 2007-01-05 2010-05-06 ユニバーシティ・オブ・チューリッヒ 疾病に特異的な結合分子および標的を提供する方法
WO2016005545A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
WO2016005547A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
AU654811B2 (en) 1990-03-20 1994-11-24 Trustees Of Columbia University In The City Of New York, The Chimeric antibodies with receptor binding ligands in place of their constant region
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5837821A (en) 1992-11-04 1998-11-17 City Of Hope Antibody construct
DE669986T1 (de) 1992-11-13 1996-10-10 Idec Pharma Corp Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung.
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2116280A1 (en) 1993-03-05 1994-09-06 Marcy E. Macdonald Huntingtin dna, protein and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
ES2242997T3 (es) 1997-03-14 2005-11-16 Biogen Idec Inc. Metodo para integrar genes en sitios especificos en celulas de mamifero por medio de recombinacion homologa y vectores para realizar el mismo.
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO1999006838A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Novel method of detecting amyloid-like fibrils or protein aggregates
WO2000030680A1 (en) 1998-11-23 2000-06-02 Idec Pharmaceuticals Corporation Tumor antigen-specific antibody-gp39 chimeric protein constructs
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
AU6234700A (en) * 1999-07-27 2001-02-13 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
EP1340088B1 (en) 2000-11-17 2007-01-17 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
BR0206985A (pt) 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP2319936A3 (en) * 2001-02-15 2012-10-17 The University of Chicago Yeast screens for agents affecting protein folding
US20030157641A1 (en) 2001-11-16 2003-08-21 Idec Pharmaceuticals Corporation Polycistronic expression of antibodies
WO2004101787A1 (ja) * 2003-05-14 2004-11-25 Japan Science And Technology Agency ハンチンチン遺伝子の発現抑制
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US8022268B2 (en) * 2007-06-11 2011-09-20 The University Of Zurich Transgenic animal model for alzheimer's disease
AU2009328505B2 (en) 2008-12-19 2014-11-27 Panima Pharmaceuticals Ag Human anti-alpha-synuclein autoantibodies
BR112013008765B8 (pt) 2010-10-11 2023-05-02 Biogen Idec Int Neuroscience Gmbh Anticorpos monoclonais anti-tau humano isolados ou um fragmento de ligação à tau dos mesmos, métodos de preparação dos mesmos, polinucleotídeo ou polinucleotídeos, vetor ou vetores, composição, método in vitro de diagnóstico ou monitoramento da progressão de uma tauopatia neurodegenerativa em um indivíduo humano, método in vitro para diagnosticar uma tauopatia neurodegenerativa em um indivíduo humano, e kit útil para o diagnóstico de uma tauopatia neurodegenerativa
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
WO2013013025A2 (en) * 2011-07-20 2013-01-24 Medimmune Limited Anti-cxcr4 antibodies and methods of use
CA2853412C (en) 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
EP3071598B1 (en) * 2013-05-29 2021-07-07 Vybion, Inc. Single chain intrabodies that alter huntingtin mutant degradation
EP4406549A3 (en) 2014-07-29 2025-01-08 Neurimmune Holding AG Human-derived anti-huntingtin (htt) antibodies and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030232052A1 (en) * 2002-01-28 2003-12-18 Ali Khoshnan Antibodies that bind to an epitope on the Huntington's disease protein
WO2005052002A2 (en) * 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
JP2010514454A (ja) * 2007-01-05 2010-05-06 ユニバーシティ・オブ・チューリッヒ 疾病に特異的な結合分子および標的を提供する方法
WO2016005545A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease
WO2016005547A1 (en) * 2014-07-10 2016-01-14 Affiris Ag Substances and methods for the use in prevention and/or treatment in huntington's disease

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BUTLER, D.C. AND MESSER, A., PLOS ONE, vol. 6, no. 12, JPN6018024768, 2011, pages 29199 - 1, ISSN: 0003827415 *
BUTLER, D.C. ET AL., PROG. NEUROBIOL., vol. 97, JPN6018024763, 2012, pages 190 - 204, ISSN: 0003827410 *
COLBY, D.W. ET AL., J. MOL. BIOL., vol. 342, JPN6018024762, 2004, pages 901 - 912, ISSN: 0003827409 *
COLBY, D.W. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 101, no. 51, JPN6018024767, 2004, pages 17616 - 17621, ISSN: 0003827414 *
HUANG, L. ET AL., INT. J. MOL. SCI., vol. 14, JPN6019007541, 2013, pages 19109 - 19127, ISSN: 0003990509 *
IIZUKA, A. ET AL., IMMUNOLOGY LETTERS, vol. 159, JPN6020007542, 15 February 2014 (2014-02-15), pages 15 - 22, ISSN: 0004224527 *
KHOSHNAN, A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 99, JPN6019007544, 2002, pages 1002 - 1007, ISSN: 0003990512 *
KHOSHNAN, A. ET AL., TRINUCLEOTIDE REPEAT PROTOCOLS, METHODS IN MOLECULAR BIOLOGY, vol. 1010, JPN6018024764, 2013, pages 231 - 251, ISSN: 0003827411 *
KLEIN, U. ET AL., IMMUNOL. REV., vol. 162, JPN6020005578, 1998, pages 261 - 280, ISSN: 0004224528 *
LECERF, J.-M. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, no. 8, JPN6018024770, 2001, pages 4764 - 4769, ISSN: 0003827417 *
MESSER, A. AND JOSHI, S.N., NEUROTHERAPEUTICS, vol. 10, JPN6019007543, 2013, pages 447 - 458, ISSN: 0003990513 *
SHEETS, M.D. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 95, JPN6018024771, 1998, pages 6157 - 6162, ISSN: 0003827418 *
SOUTHWELL, A.L. ET AL., J. NEUROSCI., vol. 28, no. 36, JPN6018024765, 2008, pages 9013 - 9020, ISSN: 0003827412 *
SOUTHWELL, A.L. ET AL., J. NEUROSCI., vol. 29, no. 43, JPN6018024766, 2009, pages 13589 - 13602, ISSN: 0003827413 *
WIENS, G.D. ET AL., J. IMMUNOL., vol. 159, JPN6018017632, 1997, pages 1293 - 1302, ISSN: 0003990511 *
WOLFGANG, W.J. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 102, no. 32, JPN6018024769, 2005, pages 11563 - 11568, ISSN: 0003827416 *

Also Published As

Publication number Publication date
AU2020217427B2 (en) 2023-10-19
IL250180A0 (en) 2017-03-30
AU2015295441B2 (en) 2020-05-14
US11401325B2 (en) 2022-08-02
CN107074937B (zh) 2021-07-27
AU2020217427A1 (en) 2020-09-03
US20220332808A1 (en) 2022-10-20
US20200392217A1 (en) 2020-12-17
AU2015295441A1 (en) 2017-02-02
CN107074937A (zh) 2017-08-18
AU2024200315A1 (en) 2024-02-08
JP2021003100A (ja) 2021-01-14
NZ728372A (en) 2021-11-26
JP2023052519A (ja) 2023-04-11
MX2022003706A (es) 2022-04-26
EP3174898A2 (en) 2017-06-07
US10556946B2 (en) 2020-02-11
CN113651887A (zh) 2021-11-16
JP7235939B2 (ja) 2023-03-09
EA201790165A1 (ru) 2017-07-31
MX391037B (es) 2025-03-21
KR102643395B1 (ko) 2024-03-11
EP4406549A2 (en) 2024-07-31
EP4406549A3 (en) 2025-01-08
JP7562168B2 (ja) 2024-10-07
WO2016016278A2 (en) 2016-02-04
MX2022003704A (es) 2022-04-26
US20170166631A1 (en) 2017-06-15
KR20170036785A (ko) 2017-04-03
WO2016016278A3 (en) 2016-03-24
IL276721A (en) 2020-09-30
MX2017001285A (es) 2017-04-25
CA2954738A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
JP7562168B2 (ja) ヒト由来抗ハンチンチン（ｈｔｔ）抗体及びその使用
JP6841449B2 (ja) トランスサイレチン（ｔｔｒ）アミロイドーシスに対する抗体療法及びそのためのヒト由来抗体
US10961322B2 (en) Human-derived anti-dipeptide repeats (DPRs) antibody
JP6225189B2 (ja) ヒト膵島アミロイドポリペプチド（ｈＩＡＰＰ）特異的抗体およびその使用
EA046697B1 (ru) Происходящие от человека антитела к гентингтину (htt) и их применение
NZ728372B2 (en) Human-derived anti-huntingtin (htt) antibodies and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180629

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190524

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190830

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200528